Preventive treatment curbs bleeding in mild, moderate hemophilia A
Long-term data show Hemlibra provides sustained control
Written by |
Long-term data support the use of Hemlibra for mild or moderate hemophilia A. (Photo by iStock)
Preventive treatment with Hemlibra (emicizumab-kxwh) kept bleeding under control for nearly three years in people with mild or moderate hemophilia A without inhibitors.
That’s according to long-term data from the Phase 3 HAVEN 6 trial (NCT04158648). The results build on earlier findings showing that Hemlibra effectively controlled bleeding and was generally well tolerated after about one year.
The new results show that bleeding rates remained low with longer treatment, with participants experiencing an estimated one bleed requiring treatment per year. Nearly all joints previously affected by repeated bleeding stopped experiencing frequent spontaneous bleeds, and no new or unexpected safety concerns emerged.
“These long-term efficacy and safety data confirm [Hemlibra] as a valuable treatment option for people with non-severe [hemophilia A],” the researchers wrote.
The study, “Emicizumab long-term outcomes and coagulation biomarkers in mild or moderate hemophilia A without inhibitors (HAVEN 6),” was published in Therapeutic Advances in Hematology. The trial was sponsored by Roche, which markets Hemlibra.
Injection approved for all ages
Hemlibra is an approved preventive (prophylactic) treatment for hemophilia A that mimics the activity of factor VIII (FVIII), the clotting protein that’s missing or deficient in people with the disease. Given by injection under the skin, it helps prevent bleeding in people with or without inhibitors, antibodies that target the FVIII given through replacement therapies and reduce their effectiveness.
In the U.S., Hemlibra is approved for people of all ages with hemophilia A, regardless of disease severity or inhibitor status. In Europe, it is approved for people with FVIII inhibitors and for those without inhibitors who have severe or moderate disease.
“Several clinical trials and real-world studies have demonstrated the safety and efficacy of [Hemlibra] prophylaxis in people with [hemophilia A], many with long-term follow-up periods,” the researchers wrote. “However, most trials primarily focused on [Hemlibra] in people with severe [hemophilia A], while data detailing the safety and efficacy for those with mild or moderate [hemophilia A] are scarce.”
HAVEN 6 was designed to help fill this gap. The trial enrolled 72 people, ages 2 to 71, with mild or moderate hemophilia A without FVIII inhibitors who were considered to need preventive treatment. Most (71%) had moderate disease, while 21 (29%) had mild disease.
Frequent bleeding was a reason for recommending preventive treatment in 41 participants (57%), including 32 (44%) with a history of frequent joint bleeding. Another 24 (33%) had target joints, or joints affected by repeated bleeding. Yet nearly half had previously received treatment only when bleeding occurred.
All participants received Hemlibra at 3 mg/kg once weekly for four weeks, followed by maintenance doses of 1.5 mg/kg weekly, 3 mg/kg every two weeks, or 6 mg/kg every four weeks.
An earlier analysis assessed outcomes after a median of 55.6 weeks, or just over one year. The latest analysis extended that follow-up to a median of 155.9 weeks, or nearly three years, to see whether Hemlibra’s benefits were maintained.
The results showed that bleeding remained well controlled with continued Hemlibra treatment. Participants experienced an estimated one bleed requiring treatment per year, similar to the 0.9 reported in the earlier analysis.
The estimated yearly rate of all bleeds, including those that did not require treatment, was 1.7, compared with 2.3 in the earlier analysis. Rates of treated bleeds also remained stable across successive years of treatment, ranging from 0.9 to 1 per year.
Throughout follow-up, 24 participants (33%) had no bleeds requiring treatment. More than two-thirds (69%) had no spontaneous bleeds requiring treatment, while 72% had no treated joint bleeds.
Bleeding into previously affected joints also became less frequent. Of the 43 target joints identified in 24 participants at the study’s start, 42 (98%) met the criteria for resolution by the latest assessment, meaning they were no longer affected by frequent spontaneous bleeding.
Hemlibra continued to be generally well tolerated, with no unexpected safety concerns emerging during longer follow-up.
Sixty-seven participants (93%) reported at least one adverse event, with 18 (25%) experiencing events considered related to treatment. These were most commonly injection-site reactions, which occurred in 13 participants (18%).
Sixteen participants (22%) experienced serious adverse events, but none were considered related to Hemlibra.
Two blood clot-related events occurred during the study. One was a kidney infarction, in which blocked blood flow damages part of the kidney, which investigators considered related to Hemlibra. Both events resolved without either participant stopping treatment.
“HAVEN 6 was the first phase 3 clinical trial to examine outcomes of [Hemlibra] in people with mild or moderate [hemophilia A], and continued analysis is important to provide further evidence on the efficacy and safety of [Hemlibra] in these populations,” the researchers wrote. “These results confirm [Hemlibra] as a suitable therapeutic option for long-term prophylactic treatment of select people with mild or moderate [hemophilia A] with severe bleeding [features].”

Leave a comment
Fill in the required fields to post. Your email address will not be published.